VIA
Virtus Investment Advisers Portfolio holdings
AUM
$296M
1-Year Return
31.42%
This Quarter Return
+9.26%
1 Year Return
+31.42%
3 Year Return
+126.24%
5 Year Return
–
10 Year Return
–
AUM
$296M
AUM Growth
-$72M
(-20%)
Cap. Flow
-$86.7M
Cap. Flow
% of AUM
-29.31%
Top 10 Holdings %
Top 10 Hldgs %
6.88%
Holding
512
New
39
Increased
197
Reduced
202
Closed
70
Top Buys
| 1 |
Constellation Energy
CEG
|
$2.01M |
| 2 |
DoorDash
DASH
|
$1.82M |
| 3 |
Veeva Systems
VEEV
|
$1.75M |
| 4 |
Cisco
CSCO
|
$1.7M |
| 5 |
State Street
STT
|
$1.69M |
Top Sells
Sector Composition
| 1 | Financials | 33.24% |
| 2 | Healthcare | 17.43% |
| 3 | Technology | 12.41% |
| 4 | Industrials | 9.1% |
| 5 | Consumer Discretionary | 4.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
351
Cartesian Therapeutics
RNAC
$277M
| $95.4K | 0.03% |
9,183
+1,023
| +13% | +$10.6K |
|
352
Tango Therapeutics
TNGX
$772M
| $95.3K | 0.03% |
18,620
-38,979
| -68% | -$200K |
|
353
Savara
SVRA
$643M
| $94.9K | 0.03% |
41,607
-7,399
| -15% | -$16.9K |
|
354
Disc Medicine
IRON
$2.11B
| $94.5K | 0.03% |
1,784
-772
| -30% | -$40.9K |
|
355
Immunovant
IMVT
$2.99B
| $94.4K | 0.03% |
5,899
-54
| -0.9% | -$864 |
|
356
Relay Therapeutics
RLAY
$710M
| $94.3K | 0.03% |
27,256
-7,089
| -21% | -$24.5K |
|
357
Celldex Therapeutics
CLDX
$1.52B
| $94K | 0.03% |
4,621
-1,587
| -26% | -$32.3K |
|
|
ITOS
358
DELISTED
iTeos Therapeutics
ITOS
| $93.9K | 0.03% |
9,422
-11,241
| -54% | -$112K |
|
359
Akero Therapeutics
AKRO
$3.58B
| $93.7K | 0.03% |
1,756
-3,898
| -69% | -$208K |
|
360
Cytokinetics
CYTK
$6.34B
| $93.6K | 0.03% |
2,832
-438
| -13% | -$14.5K |
|
361
Cogent Biosciences
COGT
$1.82B
| $93.5K | 0.03% |
13,024
-6,663
| -34% | -$47.8K |
|
|
LENZ
362
LENZ Therapeutics
LENZ
$1.2B
| $93.2K | 0.03% |
3,179
-2,155
| -40% | -$63.2K |
|
363
Arcellx
ACLX
$4.03B
| $93.1K | 0.03% |
1,414
-554
| -28% | -$36.5K |
|
364
Protagonist Therapeutics
PTGX
$3.77B
| $92.3K | 0.03% |
1,670
-2,395
| -59% | -$132K |
|
365
CG Oncology
CGON
$2.52B
| $92.2K | 0.03% |
3,548
-2,138
| -38% | -$55.6K |
|
366
Nuvalent
NUVL
$5.83B
| $92.1K | 0.03% |
1,207
-683
| -36% | -$52.1K |
|
367
Keros Therapeutics
KROS
$633M
| $92K | 0.03% |
6,894
-2,013
| -23% | -$26.9K |
|
368
Recursion Pharmaceuticals
RXRX
$2.01B
| $92K | 0.03% |
18,188
-5,330
| -23% | -$27K |
|
369
Beam Therapeutics
BEAM
$2.11B
| $91.7K | 0.03% |
5,392
-464
| -8% | -$7.89K |
|
|
MREO
370
Mereo BioPharma
MREO
$282M
| $91.7K | 0.03% |
33,825
-10,182
| -23% | -$27.6K |
|
371
Arrowhead Research
ARWR
$4.02B
| $91.6K | 0.03% |
5,797
-1,618
| -22% | -$25.6K |
|
372
Arvinas
ARVN
$575M
| $91.4K | 0.03% |
12,422
+4,104
| +49% | +$30.2K |
|
373
CureVac
CVAC
$1.21B
| $91.2K | 0.03% |
16,792
-34,504
| -67% | -$187K |
|
374
Dianthus Therapeutics
DNTH
$853M
| $90.8K | 0.03% |
4,875
-2,111
| -30% | -$39.3K |
|
375
Vir Biotechnology
VIR
$732M
| $90.8K | 0.03% |
18,014
-4,079
| -18% | -$20.6K |
|